Geode Capital Management LLC Buys 328,434 Shares of Oruka Therapeutics, Inc. (NASDAQ:ORKA)

Geode Capital Management LLC grew its stake in Oruka Therapeutics, Inc. (NASDAQ:ORKA - Free Report) by 2,348.6% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 342,418 shares of the company's stock after purchasing an additional 328,434 shares during the quarter. Geode Capital Management LLC owned approximately 0.98% of Oruka Therapeutics worth $6,643,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also modified their holdings of the company. Vanguard Group Inc. raised its holdings in Oruka Therapeutics by 4,161.2% in the 4th quarter. Vanguard Group Inc. now owns 1,610,651 shares of the company's stock valued at $31,231,000 after acquiring an additional 1,572,853 shares during the period. Franklin Resources Inc. bought a new position in shares of Oruka Therapeutics during the third quarter worth approximately $17,661,000. Wellington Management Group LLP increased its stake in shares of Oruka Therapeutics by 15.8% during the fourth quarter. Wellington Management Group LLP now owns 95,089 shares of the company's stock worth $1,844,000 after purchasing an additional 12,952 shares during the period. Charles Schwab Investment Management Inc. acquired a new stake in Oruka Therapeutics during the 4th quarter worth approximately $303,000. Finally, China Universal Asset Management Co. Ltd. bought a new stake in Oruka Therapeutics in the 4th quarter valued at $144,000. Institutional investors own 56.44% of the company's stock.

Oruka Therapeutics Price Performance

Shares of NASDAQ ORKA traded up $0.21 during mid-day trading on Thursday, hitting $10.65. 14,215 shares of the stock traded hands, compared to its average volume of 234,431. Oruka Therapeutics, Inc. has a twelve month low of $5.49 and a twelve month high of $31.13. The firm has a 50 day simple moving average of $10.01 and a two-hundred day simple moving average of $16.49. The company has a market cap of $398.75 million, a PE ratio of -1.70 and a beta of 0.47.

Oruka Therapeutics (NASDAQ:ORKA - Get Free Report) last posted its earnings results on Thursday, March 6th. The company reported ($0.49) EPS for the quarter, topping the consensus estimate of ($0.68) by $0.19. On average, equities research analysts anticipate that Oruka Therapeutics, Inc. will post -3.41 earnings per share for the current fiscal year.

Insider Buying and Selling at Oruka Therapeutics

In other news, major shareholder Venrock Healthcare Capital Par acquired 88,794 shares of Oruka Therapeutics stock in a transaction dated Friday, February 14th. The shares were bought at an average cost of $11.44 per share, with a total value of $1,015,803.36. Following the purchase, the insider now owns 4,148,428 shares in the company, valued at $47,458,016.32. This trade represents a 2.19 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at this hyperlink. In the last quarter, insiders have purchased 98,339 shares of company stock worth $1,128,456. Insiders own 22.67% of the company's stock.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on ORKA. HC Wainwright reiterated a "buy" rating and set a $45.00 price objective on shares of Oruka Therapeutics in a research report on Friday, February 7th. Wolfe Research started coverage on shares of Oruka Therapeutics in a research report on Tuesday, February 4th. They set an "outperform" rating and a $20.00 price target on the stock. Finally, Wedbush reissued an "outperform" rating and issued a $40.00 price objective on shares of Oruka Therapeutics in a report on Friday, March 7th. Seven research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to MarketBeat.com, the company currently has an average rating of "Buy" and a consensus target price of $39.86.

Oruka Therapeutics Company Profile

Oruka Therapeutics, Inc is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.